• 1. Novel benzoxepine-1,2,3-triazole hybrids: synthesis and pharmacological evaluation as potential antibacterial and anticancer agents
  Naveen Kuntala,Jhonsee Rani Telu,Venkanna Banothu,Suresh Babu Nallapati,Jaya Shree Anireddy,Sarbani Pal Med. Chem. Commun. 2015 6 1612
• 2. Efficient syntheses of pterulone, pterulone B and related analogues
  Philippe Lemaire,Geneviève Balme,Philippe Desbordes,Jean-Pierre Vors Org. Biomol. Chem. 2003 1 4209
• 3. A facile construction of oxygen heterocycles by the reaction of benzoxepine-4-carboxylates with dihaloalkanes and activated alkynes
  Veera Prasad Kasagani,Siva Hariprasad Kurma,China Raju Bhimapaka Org. Biomol. Chem. 2019 17 6645
• 4. Small hybrid heteroaromatics: resourceful biological tools in cancer research
  Vikrant Abbot,Poonam Sharma,Saurabh Dhiman,Malleshappa N. Noolvi,Harun M. Patel,Varun Bhardwaj RSC Adv. 2017 7 28313
• 5. General and practical synthesis of naphtho[2,1-d]oxazoles from naphthols and amines
  Shaofeng Wu,Furong Geng,Jianyu Dong,Long Liu,Lebin Su,Yongbo Zhou Org. Chem. Front. 2022 9 3828

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzoxepines Benzoxepines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzoxepines

Recent Advances in the Study of 2,3-Dihydro-1-benzoxepine (CAS: 14949-49-6): A Comprehensive Research Brief

The compound 2,3-dihydro-1-benzoxepine (CAS: 14949-49-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile pharmacological properties and potential therapeutic applications. This research brief synthesizes the latest findings on this heterocyclic compound, focusing on its synthesis, biological activity, and emerging roles in drug discovery. Recent studies highlight its structural uniqueness, which serves as a privileged scaffold for designing novel bioactive molecules targeting various diseases, including cancer, inflammation, and neurological disorders.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficient synthesis of 2,3-dihydro-1-benzoxepine derivatives via a palladium-catalyzed cyclization reaction, achieving yields exceeding 85%. The research emphasized the compound's stability under physiological conditions, making it a promising candidate for further pharmacokinetic optimization. Notably, modifications at the C-5 position of the benzoxepine ring were found to significantly enhance binding affinity to G-protein-coupled receptors (GPCRs), particularly those implicated in pain modulation.

In oncology research, 2,3-dihydro-1-benzoxepine-based inhibitors have shown remarkable efficacy against histone deacetylases (HDACs). A preclinical trial reported in Bioorganic & Medicinal Chemistry Letters (2024) revealed that a fluorinated derivative (14949-49-6-F) exhibited 50-fold greater selectivity for HDAC6 over other isoforms, with an IC50 of 2.3 nM. This specificity correlated with reduced toxicity in murine models while maintaining potent anti-proliferative effects in multiple myeloma cell lines. Molecular docking simulations further elucidated the compound's unique binding mode within the HDAC6 catalytic pocket.

Neuropharmacological investigations have uncovered the compound's dual activity as both a σ-1 receptor agonist and a weak NMDA receptor antagonist. A recent multi-center study demonstrated that chiral derivatives of 2,3-dihydro-1-benzoxepine displayed enantioselective neuroprotection in models of ischemic stroke, with the (R)-enantiomer showing 68% greater efficacy in reducing infarct volume compared to the (S)-form. These findings were corroborated by PET imaging studies using a carbon-11 labeled analog, which showed excellent blood-brain barrier penetration and specific binding in primate brains.

From a drug development perspective, structure-activity relationship (SAR) analyses have identified critical pharmacophores within the benzoxepine scaffold. A 2024 quantitative SAR (QSAR) model incorporating 147 derivatives achieved a predictive accuracy (q2) of 0.82 for anti-inflammatory activity, highlighting the importance of the 7-methoxy substitution pattern. Concurrently, metabolic stability studies using human liver microsomes indicated that introduction of a methyl group at the 4-position significantly improved half-life (t?/? > 6 hours) while maintaining CYP450 inhibition below safety thresholds.

Emerging applications in radiopharmaceuticals have also been reported, with technetium-99m and gallium-68 chelates of 2,3-dihydro-1-benzoxepine derivatives showing promise as tumor imaging agents. Preliminary clinical data presented at the 2024 Society of Nuclear Medicine meeting demonstrated rapid clearance from non-target tissues and high tumor-to-background ratios in breast cancer patients, suggesting potential for theranostic applications when paired with lutetium-177.

In conclusion, 2,3-dihydro-1-benzoxepine (14949-49-6) represents a multifaceted chemical entity with expanding therapeutic potential across multiple disease areas. Ongoing research continues to refine its structural optimization, with particular focus on improving target selectivity and pharmacokinetic profiles. The compound's versatility as both a standalone pharmacophore and a building block for hybrid molecules positions it as a valuable asset in contemporary drug discovery pipelines.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)